Immunosuppressive Therapy for Aplastic Anaemia.
Immunosuppressive therapy is the standard of care in aplastic anaemia in younger patients who do not have a matched sibling donor, and also in adults and older patients. Hence, a large population of patients with aplastic anaemia undergo this treatment. In patients who have responded to the first course of ATG, and have had a relapse, a second course of ATG can be administered with reasonable response rates. Response rates to first course of ATG vary from 50-85% in both children and adult. Indian data also suggests similar response rates.